secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001193125-24-017379
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics appoints Jason A. Amello as CFO effective Jan 29, 2024
-------------------------------------------------------------------------

- Jason A. Amello appointed CFO effective January 29, 2024; previously CFO at Candel Therapeutics, Akebia, and Saniona.
- Base salary of $500,000 per annum, one-time payment of $60,000, option for 750,000 shares vesting over 4 years.
- Eligible for discretionary bonus target up to 40% of base salary; severance and change-of-control provisions consistent with non-CEO executives.
- Prior interim CFO responsibilities held by CEO Gavin MacBeath and VP Finance Leiden Dworak cease as of Start Date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524017379/0001193125-24-017379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524017379/d683269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-017379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer